Xoma Royalty CORP Schedule 13D activist filings

XOMA Royalty Corp. announced the completion of its merger with Ligand Pharmaceuticals Incorporated, resulting in the cessation of beneficial ownership for Biotechnology Value Fund L.P. and its affiliates.

BVF Partners converted Series X Preferred Stock into 5,003,000 shares of XOMA Royalty Corp common stock, increasing their beneficial ownership to 43.3%.

Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty Corporation in an all-cash transaction valued at $39.00 per share plus contingent value rights.

XOMA Royalty Corp. announces a merger agreement with Ligand Pharmaceuticals Inc., with key shareholders entering a support agreement to vote in favor of the transaction.

Biotechnology Value Fund and its affiliates have filed an amended Schedule 13D, disclosing a reduction in their beneficial ownership of XOMA Royalty Corp common stock to 21.6% following a private sale of 392,723 shares at $27.10 per share.

Biotechnology Value Fund (BVF) and its affiliated entities have significantly reduced their beneficial ownership in XOMA Royalty Corp, selling over 650,000 shares in a private transaction.